PCN115 HEAD-TO-HEAD COMPARISONS OF QUALITY OF LIFE INSTRUMENTS FOR YOUNG ADULT SURVIVORS OF CHILDHOOD AND ADOLESCENT CANCER  by Huang, IC et al.
Abstracts A45
sores), and medication-related risks (liver failure, blood clot). OS was held constant 
at 32 months. Trade-off questions were based on predetermined experimental design 
with known statistical properties. Random-parameters logit model was used to esti-
mate a preference weight for each attribute level. Preference weights were used to 
calculate maximum levels of risks patients were willing to accept for increases in PFS. 
RESULTS: A total of 138 US subjects completed the survey. PFS was the most impor-
tant attribute to patients over the range of levels included in the survey, while remain-
ing attributes were ranked in order of importance as: fatigue, diarrhea, liver failure, 
hand-foot syndrome, blood clot, mouth sores. Increasing PFS by 10 months was as 
important as avoiding severe fatigue and 2-times as important as avoiding severe 
mouth sores. Patients were willing to accept blood-clot risks up to 5.5% (95% CI: 
3.6%–8.6%) and liver-failure risks up to 3.6% (95% CI: 2.6%–4.8%) to increase PFS 
by 10 months. CONCLUSIONS: PFS is a clinical outcome that is important to RCC 
patients. Patients were willing to accept higher treatment-related risks to increase PFS.
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PRO LABELLING CLAIMS IN ANTINEOPLASTIC AGENTS
Caron M, Emery MP
MAPI Research Trust, Lyon, France
OBJECTIVES: To review PRO labelling claims achieved in antineoplastic products in 
Europe and in the US. METHODS: PROLabels database was searched with neoplasm 
and oncology as keywords to identify antineoplastic agents with PRO labeling claims 
approved or revised in Europe since 1995 and in the US since 1998. FDA and EMEA 
websites and guidances were reviewed. Anti-emetic and analgesic products were not 
included. RESULTS: Among the 101 antineoplastic products approved, 18 were 
identiﬁed with PRO claims—10 in the U.S, 8 in Europe (including one in both agen-
cies)—for 11 different indications: non-small cell lung carcinoma, prostatic neoplasms, 
small cell lung carcinoma, Kaposi sarcoma, chronic myeloid leukemia, astrocytoma, 
pleural malignant mesothelioma, breast neoplasms, head & neck neoplasms, stomach 
neoplasms and colorectal neoplasms. Survival was primary endpoint for 12 products. 
Other primary endpoints included time to progression, response rate and response 
duration. PROs included in labels were primary endpoints in only two cases: one 
product used in prostatic neoplasms (improvement in pain) and one product approved 
for pancreatic neoplasms (clinical beneﬁt response including pain intensity, use of 
rescue medication and performance status). Both products were approved by the FDA. 
Health-related quality of life was clearly mentioned in the label of 7 products (4 
approved by the EMEA including 2 approved after the publication of the EMEA and 
FDA guidances, and 3 by the FDA, all approved before the publication of the guid-
ances). Of these 7 products, 3 approved by the EMEA and 1 by the FDA had an 
indication for non-small cell lung carcinoma. CONCLUSIONS: PROs are rarely used 
as primary endpoints in approval of antineoplastic agents except for assessing pallia-
tive response. When assessed, health-related quality of life is used as a supportive 
endpoint, and more often associated with non-small cell lung carcinoma, especially in 
Europe.
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LITERATURE REVIEW AND PRODUCT LABEL CLAIM REVIEW FOR THE 
DEVELOPMENT OF A PATIENT-REPORTED OUTCOME RESEARCH 
STRATEGY FOR CANCER-RELATED ANEMIA
Hackshaw MD, Brown J
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: An appraisal of patient-reported outcome (PRO) endpoints and exist-
ing instruments to measure such endpoints was conducted to identify and critically 
review potentially relevant and appropriate instruments for use in clinical trials of 
cancer-related anemia (CRA). The purpose of the study was to determine what PRO 
endpoints and instruments have been used to assess the impact of treatment in reduc-
ing CRA symptoms, and whether the instruments identiﬁed were likely to be of the 
standard acceptable by regulatory authorities to support a label claim. METHODS: 
A systematic search and review of 1486 published scientiﬁc abstracts was conducted 
using MEDLINE and EMBASE, as well as the supporting statements in regulatory 
agency labels for drugs used in the treatment of anemia. Consistency of the identiﬁed 
PRO measures and their psychometric properties with the current Food and Drug 
Administration (FDA) draft guidance on PROs supporting a labeling claim was also 
evaluated. RESULTS: A total of 29 instruments were identiﬁed. Four instruments were 
found to support a label claim or used speciﬁcally in the CRA population (FACT-F, 
FACT-An, CLAS/LASA, EORTC QLQ-C30); these were assessed further. Twenty-ﬁve 
were excluded from further assessment because they were speciﬁc to a particular 
disease other than cancer and covered aspects speciﬁc to these diseases which were 
not relevant to the CRA population. Other exclusion reasons included measurement 
of general health or health-related quality of life (HRQOL) and other symptoms that 
were neither speciﬁc to cancer nor anemia. CONCLUSIONS: None of the four instru-
ments assessed were found to meet all the criteria in the FDA draft guidance; however, 
the ﬁndings help inform the design of new PRO instruments for CRA.
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HEALTH RELATED QUALITY OF LIFE, FEAR OF RECURRENCE, IMPACT 
OF EVENTS, ILLNESS INTRUSIVENESS AND PSYHOLOGICAL DISTRESS 
IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS
Sansgiry S1, Lerner SP2, Amiel GE2, Mei M1, Latini DM1
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OBJECTIVES: The purpose of this study was to explore differences among Veterans 
and private-patients on health related quality of life (HRQOL), fear of recurrence 
(FOR), impact of events (IE), illness intrusiveness (IITF) and psychological distress in 
non-muscle invasive bladder cancer (NMIBC) patients and provide direction for 
further study. METHODS: Cross sectional study design was used. Participants were 
drawn from a large private hospital (N = 38) and Veterans Affairs hospital (N = 29) 
in the southeast United States. HRQOL was measured with EORTC-QLQ-C30. FOR 
was measured with 5-item measure used in the Cancer of the Prostate Strategic 
Research Endeavor study. The IE Scale measures subjective response to stress and 
consists of two subscales, intrusive thoughts and avoidance. The IITF measure assesses 
impact of illness on functioning and consists of three subscales, intimacy, instrumental 
life and relationship-personal development. Psychological distress was measured with 
the Brief Symptom Index (BSI), an 18-item measure. Differences among Veterans vs. 
private-patients were assessed with student t-test or chi-square as appropriate. Analy-
ses were performed using the SAS v9.1.3. RESULTS: Majority of respondents were 
older (mean age at diagnosis 65.4(± 8.8) years), white (91.1%), males (83.6%), 
married (70.2%) and largest percentage (35.8%) reported getting some college educa-
tion. Veterans group did not differ from private-patients on age, education, ethnicity, 
relationship status, number of bladder cancer treatments received or time since diag-
nosis (years) (p > 0.05), but differed signiﬁcantly on gender (p = 0.0016). Number of 
comorbidities were also higher in the Veterans group (p = 0.0214). Veterans indicated 
signiﬁcantly higher FOR, psychological distress, illness intrusiveness on intimacy and 
instrumental life, and lower HRQOL compared to private-patients (p < 0.05). CON-
CLUSIONS: Veterans had higher level of FOR and psychological distress but lower 
HRQOL, than private-patients. Interventions to manage patients’ fear of recurrence, 
psychological distress and help them adapt to altered routine may assist NMIBC 
patients.
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EXPLORING THE BURDEN OF ILLNESS ON NEWLY DIAGNOSED 
ESOPHAGEAL CANCER PATIENTS IN TAIWAN –PRELIMINARY 
ANALYSIS
Lin HW, Ku CH, Lee RF, Shih TP, Liu YY, Lin CY
China Medical University, Taichung, Taiwan
OBJECTIVES: Esophageal cancer (EC) is the seventh cancer among male patients in 
Taiwan. Difﬁculty swallowing makes EC patients vulnerable to nutritional challenges 
and impacts their treatment outcomes and well-being. The aims of this study are to 
explore the EC patients’ burden of illness on nutritional and well-being aspects. 
METHODS: A longitudinal observation study is conducting to recruit newly diag-
nosed EC patients from the CMU Hospital in Taichung, Taiwan since June 2009. 
Fresh EC patients were assessed before (T0) and after receiving any main treatments 
(T1 [1-month], T2 [3-month], T3 [6-month] after treatment(s)) if it is not impossible. 
Well trained interviewers solicited patients’ responses on 1) Nutritional Risk Screen 
(NRS-2002); 2) Chinese versions of EQ-5D and FACT-E. The descriptive analyses 
were performed to examine the trends among different stages of EC patients. 
RESULTS: Up to the date of analysis(December 31, 2009), of 27 recruited EC patients, 
average age was 53 ± 9 years-old and more than 90% were diagnosed with squamous 
cell carcinoma (³85% with clinical stage at III and above). There were 23, 14, 5 and 
2 patients completed the T0, T1, T2 and T3 assessments, respectively. Approximately 
70% and 80% of patients at T0 and T2 had NR-2002S scored greater than 3 (with 
deﬁned risk of malnutrition). From T0 to T3, upon the solicited, completed responses, 
patients seemed to be deteriorated on the daily activities and social well-being (i.e., 
self-care, usual activity of EQ-5D, and physical and social well-being of FACT-E) but 
improve on esophageal cancer related symptoms and signs (additional concerns of EC) 
after treatments. CONCLUSIONS: This preliminary analysis showed the extent of EC 
patients’ burden of illness and its change over time. Further assessments are necessary 
to facilitate the decision making about appropriate management of EC patients on the 
aspect of nutrition and health-related quality of life.
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HEAD-TO-HEAD COMPARISONS OF QUALITY OF LIFE INSTRUMENTS 
FOR YOUNG ADULT SURVIVORS OF CHILDHOOD AND ADOLESCENT 
CANCER
Huang IC1, Quinn G2, Shenkman E1, Shearer P1
1University of Florida, Gainesville, FL, USA, 2H. Lee Mofﬁtt Cancer Center and Research 
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OBJECTIVES: Although several health-related quality of life (HRQOL) instruments 
exist for adult cancer survivors, little attention has been paid to identify appropriate 
instruments for young adult survivors of childhood and adolescent cancer (YASCAC). 
We aim to make head-to-head comparisons of 3 HRQOL instruments for YASCAC. 
METHODS: We collected data via telephone interviews between 05/01/2009 and 
09/30/2009 from 141 YASCAC who were off therapy at least 2 years without cancer 
and enrolled in the CSP and/or the UF Tumor Registry. Each subject reported his/her 
late effects (yes/no) and HRQOL. HRQOL was measured using the Quality of Life 
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in Adult Cancer Survivor (QLACS), Quality of Life-Cancer Survivor (QOL-CS), and 
SF-36. We used Cronbach’s alpha coefﬁcient to estimate reliability. We estimated 
Pearson’s correlation coefﬁcients to examine convergent/discriminant validity. We 
hypothesized homogenous domains (e.g., physical functioning and pain) among 3 
instruments would be strongly correlated with each other compared to heterogeneous 
domains (e.g., physical vs. psychological functioning). We used effect sizes to evaluate 
late effect known-groups validity which is the extent to which HRQOL scores differ 
by late effects (yes/no). RESULTS: Cronbach’s alpha coefﬁcients were acceptable (>0.7) 
for all domains. Physical domains of the QLACS (e.g., pain) were strongly correlated 
with the SF-36’s physical component summary (PCS), but weakly with mental com-
ponent summary (MCS). Mental domains of the QLACS (e.g., negative feelings) were 
strongly correlated with MCS, but weakly with PCS. However, both physical and 
mental domains of the QOL-CS were strongly correlated with MCS compared to with 
PCS, suggesting poor convergent/discriminant validity. Effect sizes suggest greater 
discrimination (>0.5) by the QOL-CS and SF-36 for late effect known-groups com-
pared to the QLACS. CONCLUSIONS: The 3 HRQOL instruments are not superior 
to each other. We suggest using item response theory to select high quality items from 
different instruments to measure HRQOL for YASCAC more meaningfully.
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PILOT STUDY FOR EVULATION OF OUTCOMES OF BREAST CANCER 
WITH SPECIAL FOCUS ON ECONOMIC IMPACT AND QUALITY OF LIFE
Nagappa AN, Punnackal DA, Udupa N, Vadhiraja BM
Manipal University, Manipal, India
OBJECTIVES: A pilot study was conducted to evaluate the outcomes of breast cancer 
and its treatment focusing on economic impact and quality of life in a hospital setting 
METHODS: Patient interviews were held to measure the economic out come and 
standardized tool EORTC QLQ C 30 and its breast speciﬁc module QLQ BR 23 was 
utilized to measure the quality of life. Twenty-seven subjects diagnosed at different 
stages of the disease were studied. RESULTS: The respondent’s age ranged between 
33–65 yrs with mean age 49.65(SD = 9.011). The educational status was classiﬁed in 
to four groups, illiterate to university viz; illiterate (25.92%), primary education 
(22.22%) secondary education (48.14%), and college studies (3.70%). The marital 
status of the respondents was classiﬁed as married and widowed, 81.48% and 18.51% 
respectively. The distribution of respondents according to TNM staging of breast 
cancer was observed as ﬁrst stage (none), stage II (29.62%), stage III (40.74%), and 
stage IV (14.81%). All patients were treated with a multimodality approach for 
management. The cost analysis revealed that there are signiﬁcant differences among 
different modalities of treatments viz; module one (Rs.1.00 lakh), module two 
(Rs.1.57 lakh) and module three (Rs.1.09 lakh).The quality of life study revealed that 
there are differences in the functional scales as well as symptoms scales among the 
patients treated with different treatment regimens. CONCLUSIONS: Breast cancer is 
a disease, where there is a lot of scope for pharmaceutical care in order to improve 
the functional scales and global health and to decrease symptoms scales of breast 
cancer patients. Key words; Breast cancer, outcomes, quality of life.
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QUALITY OF LIFE SCALE FOR PATIENTS WITH HAND-FOOT 
SYNDROME : FIRST RESULTS
Sibaud V1, Rahhali N2, Charles T3
1Institut Claudius Regaud, Toulouse, France, 2PFSA, Boulogne, France, 3CREES PFSA, 
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OBJECTIVES: The aim of this study is to develop and validate a hand-foot syndrome-
speciﬁc quality of life scale to be able to measure the impact of the condition on 
patients and to be able to assess the value of certain speciﬁc treatments in this indica-
tion. METHODS: Forty-four patients were included during clinical consultation. 
RESULTS: A total of 61.91% of patients declared having their ﬁrst episode of HSFR. 
The mean age was 56.5 years and the population was represented by 75% of female. 
A total of 2.27%, 29.55%, 38.64% and 29.55% of patients graded 0, 1, 2, 3 in the 
disease severity; 14.63% of patients have their HFSR located on the hands, 24.39% 
on feet, 60.98% on both hands and feet. The mean global score of the HFS 14 ques-
tionnaire is 37.63 (2–100). The mean score in grade 1 patients is 16.68, 41.18 in grade 
2 patients, 53.09 in grade 3 patients. There is a signiﬁcant difference between these 3 
mean scores (p < 0.0001). The HFS 14 score is positively and signiﬁcantly correlated 
to the DLQI and the Skindex-16 scores. The correlation coefﬁcient between the HFS 
14 and the DLQI questionnaires is 0.71324 (p < 0.0001). The correlation coefﬁcient 
between the HFS 14 and the Skindex16 questionnaires is 0.7347 (p < 0.0001). The 
HFS 14 score is negatively correlated with the SF-12 score. The correlation coefﬁcient 
is signiﬁcantly different from 0 concerning physical dimension (p = 0.0027). The cor-
relation coefﬁcient is not signiﬁcantly different from 0 concerning the mental dimen-
sion. The p-value is 0.4457.The HFS 14 score is positively and signiﬁcantly correlated 
to the pain measured by the visual analogue scale (p < 0.0001). The correlation is 
estimated 0.68142. CONCLUSIONS: The HFS 14 (or short version) meets require-
ments of QoL scale and is easy to use. The questionnaire is able to assess the clinical 
efﬁcacy of new speciﬁc treatments developed for HFSR.
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USING DISCRETE CHOICE EXPERIMENTS TO ESTIMATE THE 
MARGINAL WILLINGNESS TO PAY OF INSURANCE PREMIUM FOR 
STOMACH CANCER TREATMENT IN KOREA
Jo C, Cho DH
Hallym University, Chuncheon, South Korea
OBJECTIVES: This study, using DCE method, ﬁgures out the characteristics of the 
decision-making for stomach cancer treatment and investigates the attributes affecting 
the respondents’ choice. Also it ascertains marginal willingness to pay and relative 
preferences for stomach cancer treatment among the general population of 600 
respondents in Korea. METHODS: In the survey, the respondents are asked to 
choose more than one discrete choice option, resulting in multiple observations for 
each individual. For each pair-wise comparison of choice set, the respondent will 
make a choice among three alternatives; A, B, or opt out. Thus, the nested-logit 
model using full maximum likelihood allows us to empirically estimate multi-levels 
of dependent variables. For the robustness check of our empirical results, we try 
considering the nature of distribution of error terms in the utility function in several 
ways. The survey questionnaire includes four attributes associated with stomach 
cancer in Korea (incidence rates, survival rates in ﬁve years after treatment, total 
treatment costs, and monthly insurance premium), socio-economic status, antecedent 
variables, along with questions regarding risk averseness and subjective health evalu-
ation. RESULTS: The estimates of MWTP between survival rate and monthly insur-
ance premium and MTWP between total treatment costs and monthly insurance 
premium, by employing “Hybrid Conditional Fixed Effects Logit Model” to ﬁgure 
out the existence of heterogeneity of any observed and unobserved components, are 
reﬂecting reasonable range of 176 KRW∼194 KRW and 5408 KRW∼6945 KRW, 
respectively. CONCLUSIONS: Compared to female counterparts, male respondents 
have higher MWTP of monthly insurance premium for two related attributes. Besides, 
currently married respondents, with higher income, and higher educational attain-
ments have more MWTP compared to their respective counterparts. One interesting 
point is that dependents’ MWTP is higher than that of insurance premium payers 
even after controlling for any other variables.
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USING DISCRETE CHOICE EXPERIMENTS TO ESTIMATE THE 
WILLINGNESS TO PAY FOR CANCER TREATMENT IN KOREA: A 
GENERAL POPULATION STUDY
Jo C
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OBJECTIVES: This study, using DCE method, ﬁgures out the characteristics of the 
decision-making for cancer treatment and investigates the attributes affecting the 
respondents’ choice. Also it ascertains marginal willingness to pay and relative prefer-
ences for cancer treatment among the general population. METHODS: In the survey, 
the respondents are asked to choose more than one discrete choice option, resulting 
in multiple observations for each individual. For each pair-wise comparison of choice 
set, the respondent will make a choice among three alternatives; A, B, or opt out. 
Thus, the nested-logit model using full maximum likelihood allows us to empirically 
estimate multi-levels of dependent variables. For the robustness check of our empirical 
results, we try considering the nature of distribution of error terms in the utility func-
tion in several ways. The key assumption of logit models is the independence of 
irrelevant alternatives (IIA), which results from the assumption that other alternatives 
are independent. The validity of IIA assumption can be simply conducted by a 
Hausman-McFadden test. We also consider an alternative speciﬁcation where error 
terms are independently, but not identically distributed. And ﬁnally stand errors are 
calculated by using bootstrapping and compared to the previous results. RESULTS: 
In this DCE study, evidence of reliability was found at both input and output level. 
The estimates of MWTP between survival rate and monthly insurance premium and 
MTWP between total treatment costs and monthly insurance premium, by employing 
“Hybrid Conditional Fixed Effects Logit Model” to ﬁgure out the existence of het-
erogeneity of any observed and unobserved components, are reﬂecting reasonable 
range of 817 KRW∼1,324KRW, and 23,690 KRW∼38,139 KRW, respectively. CON-
CLUSIONS: Compared to female counterparts, male respondents have higher MWTP 
of monthly insurance premium for two related attributes. Besides, currently married 
respondents, with higher income, and higher educational attainments have more 
MWTP compared to their respective counterparts.
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USING DISCRETE CHOICE EXPERIMENTS TO ESTIMATE THE 
MARGINAL WILLINGNESS TO PAY OF INSURANCE PREMIUM FOR 
LUNG CANCER TREATMENT IN KOREA
Jo C
Hallym University, Chuncheon, South Korea
OBJECTIVES: This study, using DCE method, ﬁgures out the characteristics of the 
decision-making for lung cancer treatment and investigates the attributes affecting the 
respondents’ choice. Also it ascertains marginal willingness to pay and relative prefer-
ences for lung cancer treatment among the general population of 600 respondents in 
Korea. METHODS: In the survey, the respondents are asked to choose more than one 
discrete choice option, resulting in multiple observations for each individual. For each 
pair-wise comparison of choice set, the respondent will make a choice among three 
alternatives; A, B, or opt out. Thus, the nested-logit model using full maximum likeli-
hood allows us to empirically estimate multi-levels of dependent variables. For the 
robustness check of our empirical results, we try considering the nature of distribution 
